ABCD1 — ATP Binding Cassette Subfamily D Member 1

ABCD1 — ATP Binding Cassette Subfamily D Member 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ABCD1 — ATP Binding Cassette Subfamily D Member 1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ABCD1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ATP Binding Cassette Subfamily D Member 1 (ALDP)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>Xq28</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/215" target="_blank">215</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101986" target="_blank">ENSG00000101986</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/300100" target="_blank">300100</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P33897" target="_blank">P33897</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[X-Linked Adrenoleukodystrophy](/diseases/x-linked-adrenoleukodystrophy), [Zellweger Spectrum](/diseases/zellweger-syndrome), Peroxisomal Biogenesis Disorders</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (oligodendrocytes, astrocytes), adrenal cortex, liver, kidney, peroxisomes</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>,

ABCD1 — ATP Binding Cassette Subfamily D Member 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ABCD1 — ATP Binding Cassette Subfamily D Member 1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ABCD1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ATP Binding Cassette Subfamily D Member 1 (ALDP)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>Xq28</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/215" target="_blank">215</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101986" target="_blank">ENSG00000101986</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/300100" target="_blank">300100</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P33897" target="_blank">P33897</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[X-Linked Adrenoleukodystrophy](/diseases/x-linked-adrenoleukodystrophy), [Zellweger Spectrum](/diseases/zellweger-syndrome), Peroxisomal Biogenesis Disorders</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (oligodendrocytes, astrocytes), adrenal cortex, liver, kidney, peroxisomes</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/neurodegeneration" style="color:#ef9a9a">Neurodegeneration</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">35 edges</a></td>
</tr>
</table>

ABCD1 — ATP Binding Cassette Subfamily D Member 1

Pathway Diagram

Overview

ABCD1 (ATP-binding cassette subfamily D member 1), also known as ALDP (adrenoleukodystrophy protein), is a peroxisomal half-transporter that plays an essential role in the import and metabolism of very long-chain fatty acids (VLCFAs) [1]. Located on the peroxisomal membrane, ABCD1 forms homodimers that transport VLCFAs into peroxisomes for β-oxidation. Mutations in ABCD1 cause [X-linked adrenoleukodystrophy](/diseases/x-linked-adrenoleukodystrophy) (X-ALD), one of the most common peroxisomal disorders and a progressive neurodegenerative condition characterized by demyelination, adrenal insufficiency, and neurodegeneration [2].[@cy2021]

Introduction

ABCD1 was first identified in 1993 when mutations were found to cause X-linked adrenoleukodystrophy, a devastating peroxisomal disorder that affects approximately 1 in 15,000-20,000 males [1]. The discovery established ABCD1 as the first gene known to cause a human peroxisomal leukodystrophy and opened new avenues for understanding peroxisomal biology and developing therapies for this class of diseases.

The protein belongs to the ATP-binding cassette (ABC) transporter family, specifically the subfamily D, which in humans consists of four members (ABCD1-4). Unlike many ABC transporters that function at the plasma membrane, ABCD1 operates at the peroxisomal membrane, where it imports substrates for metabolic processing. This unique subcellular localization and its critical role in VLCFA metabolism make ABCD1 essential for normal brain function.

X-ALD demonstrates the critical importance of peroxisomal function in the nervous system.[@i2010] The disease manifests with a spectrum of phenotypes, from childhood cerebral ALD (cALD) with devastating demyelination to adult-onset adrenomyelopathy (AMN) with gradual spinal cord degeneration. Understanding ABCD1 function and dysfunction provides insights not only into X-ALD but also into broader mechanisms of peroxisome-dependent neurodegeneration.

Gene Structure and Organization

Genomic Location

The ABCD1 gene is located on the long arm of the X chromosome at position Xq28. It spans approximately 16.5 kb and consists of 10 exons. The gene encodes a protein of 745 amino acids with a molecular weight of approximately 80 kDa.

Regulatory Elements

The ABCD1 promoter contains several regulatory elements:

• PPARα response elements (PPREs): Allow regulation by peroxisome proliferator-activated receptor alpha
• FOXO1 binding sites: Enable glucose-regulated expression
• NF-κB elements: Permit inflammatory-mediated regulation

Evolutionary Conservation

ABCD1 orthologs are found throughout vertebrates, with high conservation. The protein contains characteristic ABC transporter domains:

• N-terminal transmembrane domain: Six transmembrane helices
• C-terminal nucleotide-binding domain (NBD): ATP-binding cassette with Walker A (P-loop), Walker B, and ABC signature motifs

Protein Structure and Function

Structural Organization

ABCD1 is a peroxisomal half-transporter that must dimerize to form a functional transporter:

The protein localizes to the peroxisomal membrane with both N- and C-termini facing the cytosol, a configuration shared with other peroxisomal ABC transporters (ABCD2, ABCD3).

Mechanistic Function

ABCD1 functions as an importer of VLCFAs into peroxisomes:

Substrate Specificity

ABCD1 primarily transports:

• Very long-chain fatty acids (VLCFAs): C24-C30 saturated and monounsaturated fatty acids
• Branched-chain fatty acids: Including pristanic acid
• Bile acid intermediates: C27-bile acids

Normal Physiological Function

Peroxisomal Fatty Acid Metabolism

In peroxisomes, imported VLCFAs undergo β-oxidation, which:

• Shortens VLCFAs to more manageable chain lengths
• Generates acetyl-CoA and propionyl-CoA for energy or biosynthesis
• Prevents accumulation of toxic VLCFAs in membranes

Myelin Maintenance

In the central nervous system, ABCD1 function is critical for:

• Oligodendrocyte function: VLCFAs are components of myelin lipids
• Membrane homeostasis: Proper fatty acid composition of neuronal membranes
• Energy metabolism: Peroxisomal β-oxidation provides energy for myelination

Adrenal Steroidogenesis

The adrenal cortex expresses high levels of ABCD1, where VLCFAs are essential for:

• Cholesterol trafficking for steroid hormone synthesis
• Membrane composition of steroidogenic cells
• Proper adrenal function

Role in Neurodegeneration

X-Linked Adrenoleukodystrophy (X-ALD)

ABCD1 mutations cause X-ALD, the most common peroxisomal disorder:

Cerebral ALD (cALD): Childhood-onset (4-10 years) progressive demyelination

• Behavioral changes and cognitive decline
• Motor impairment and vision problems
• Rapid progression to vegetative state

• Gradual spastic paresis
• Bowel/bladder dysfunction
• Slower progression than cALD

• Primary adrenal failure
• Requires corticosteroid replacement

Molecular Pathogenesis

ABCD1 deficiency leads to:

Neuroinflammation

X-ALD demonstrates the intersection of peroxisomal dysfunction and neuroinflammation [3]:

• Activated microglia in lesion areas
• Elevated cytokines (IL-1β, TNF-α, IL-6)
• Blood-brain barrier disruption
• Immune cell infiltration

Oligodendrocyte Vulnerability

ABCD1 is essential for oligodendrocyte function [4]:

• VLCFAs are critical myelin components
• Peroxisomes provide energy for myelination
• Deficiency leads to oligodendrocyte death

Therapeutic Approaches

Dietary Therapy

Loren's Oil: A 4:1 mixture of oleic acid (C18:1) to erucic acid (C22:1)

• Reduces VLCFA synthesis
• Does not reverse existing demyelination
• Requires early initiation for benefit [5]

• Complements Loren's oil therapy
• Requires careful nutritional monitoring

Pharmacological Approaches

PPAR Agonists: Peroxisome proliferator-activated receptor agonists

• Induce peroxisome proliferation
• May enhance alternative fatty acid oxidation pathways
• Clinical trials ongoing [6]

• May slow VLCFA accumulation
• Not curative

Cell-Based Therapy

Hematopoietic Stem Cell Transplantation (HSCT):

• Provides functional ALD protein via bone marrow-derived cells
• Can stabilize cALD when performed early
• Significant risks including graft-versus-host disease [7]

Gene Therapy

Lenti-D (LentiGlobin): Autologous CD34+ cells transduced with lentiviral vector containing functional ABCD1

• FDA approved (2022) for cALD
• Eliminates need for HSCT
• Sustained clinical benefit in trials [8]

• Direct CNS delivery under investigation
• May restore peroxisomal function locally

Related Proteins and Pathways

Peroxisomal ABC Transporters

| Protein | Gene | Function | Compensation |
|---------|------|----------|--------------|
| ALDP | ABCD1 | VLCFA import | Primary |
| ALDR | ABCD2 | VLCFA transport | Partial |
| PMP70 | ABCD3 | Dicarboxylic acid transport | Limited |

Peroxisome Biogenesis

• [PEX proteins](/mechanisms/peroxisome-biogenesis) — Peroxin family
• [PMP70](/genes/abcab3) — ABCD3 paralog
• [Peroxisomal bifunctional enzyme](/proteins/pbe-enzyme) — β-oxidation

Fatty Acid Metabolism

• [VLCFA metabolism](/mechanisms/vlcfa-metabolism)
• [β-oxidation pathway](/mechanisms/beta-oxidation)
• [PPAR signaling](/mechanisms/ppar-signaling)

Key Publications

External Links

• NCBI Gene: [https://www.ncbi.nlm.nih.gov/gene/215](https://www.ncbi.nlm.nih.gov/gene/215)
• UniProt: [https://www.uniprot.org/uniprot/P33897](https://www.uniprot.org/uniprot/P33897)
• Ensembl: [https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101986](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101986)
• OMIM: [https://omim.org/entry/300100](https://omim.org/entry/300100)
• ALD Connect: [https://www.aldfoundation.org/](https://www.aldfoundation.org/)

Related Pages

• [X-Linked Adrenoleukodystrophy](/diseases/x-linked-adrenoleukodystrophy)
• [Peroxisome Function](/mechanisms/peroxisome-function)
• [Peroxisomal Biogenesis Disorders](/diseases/peroxisomal-biopogenesis-disorders)
• [White Matter Disorders](/diseases/white-matter-disorders)
• [Demyelination Mechanisms](/mechanisms/demyelination)
• [Oligodendrocyte](/cell-types/oligodendrocyte)
• [Astrocyte](/cell-types/astrocyte)
• [Genes Index](/genes)

References

Conclusion

ABCD1 represents a critical intersection between peroxisomal biology and neurodegenerative disease. Its role in VLCFA metabolism is essential for normal brain function, and deficiency leads to the devastating demyelination seen in X-ALD. The development of gene therapy (Lenti-D) represents a landmark achievement in treating this previously untreatable disease. Ongoing research continues to explore gene therapy optimization, early intervention strategies, and therapies targeting the downstream pathogenic mechanisms of ABCD1 deficiency.

Additional Research Directions

Newborn Screening

Newborn screening for X-ALD using dried blood spot VLCFA measurement has been implemented in multiple US states and countries [9]:

• Early detection: Identifies affected males before symptom onset
• Intervention window: Allows pre-symptomatic treatment
• Family planning: Enables carrier detection in mothers
• Outcome improvement: Early HSCT or gene therapy shows better outcomes

Biomarkers

Several biomarkers are used in X-ALD management:

• Plasma VLCFA levels: C26:0 and C26:1/C22:0 ratio
• MRI lesion load: Quantitative assessment of demyelination
• Neurofilament light chain (NfL): Blood biomarker of neuronal injury
• Adrenal function tests: ACTH stimulation testing

Gene Structure Details

The ABCD1 gene contains specific mutations:

• Missense mutations: Most common (~60% of mutations)
• Nonsense mutations: ~15% of cases
• Frameshift mutations: ~15% of cases
• Large deletions: ~10% of cases

Protein-Protein Interactions

ABCD1 interacts with several proteins:

• ABCD2: Forms heterodimers with partial functional compensation
• PEX proteins: Required for peroxisomal targeting
• DJ-1 (PARK7): Associated with oxidative stress response
• Pex11β: Peroxisome proliferation and dynamics

Model Systems

Research uses multiple model systems:

• Mouse models: Abcd1 knockout mice show VLCFA accumulation but not severe cALD
• Patient-derived iPSCs: Differentiated neurons and oligodendrocytes
• Zebrafish models: Accessible developmental studies
• Cell culture: Fibroblasts from patients

Comparison with Other ABC Transporters

| Feature | ABCD1 | ABCD2 | ABCD3 |
|---------|-------|-------|-------|
| Primary substrate | VLCFAs | VLCFAs | Dicarboxylic acids |
| Expression | Brain, adrenal | Brain, testis | Liver, kidney |
| Compensation | Limited | Partial | Minimal |

Cellular Stress Responses

ABCD1 deficiency triggers multiple stress pathways:

• ER stress: Unfolded protein response activation
• Oxidative stress: Mitochondrial dysfunction
• Inflammasome activation: NLRP3 inflammasome
• Autophagy: Selective autophagy of peroxisomes (pexophagy)

Future Therapeutic Directions

Emerging therapies include:

• Small molecule correctors: Compounds that restore mutant protein function
• Combination therapies: Gene therapy plus pharmacological approaches
• Targeted delivery: CNS-specific gene therapy vectors
• Symptom modifiers: Neuroprotective and remyelinating compounds

Disease Spectrum Details

Childhood Cerebral ALD (cALD)

The most severe phenotype:

• Age of onset: 3-12 years (median 7 years)
• Progression: Rapid over 2-4 years
• Features: Behavioral changes, cognitive decline, motor impairment, vision loss
• MRI: Confluent demyelinating lesions in parieto-occipital white matter

Adult-Onset Adrenomyelopathy (AMN)

Spinal cord predominant:

• Age of onset: 20-50 years (median 30s)
• Progression: Gradual over decades
• Features: Spastic paraparesis, bladder dysfunction, peripheral neuropathy
• MRI: Spinal cord atrophy, less cerebral involvement

Asymptomatic/Mild Phenotype

Some mutation carriers remain asymptomatic:

• Variable penetrance
• May develop adrenal insufficiency without neurological symptoms
• Requires monitoring

Female Carriers

Heterozygous females can develop symptoms:

• ~50% develop symptoms by age 60
• Often milder than male presentations
• May have adrenal involvement

Adrenal-Only Disease

Some patients present with primary adrenal insufficiency:

• May develop neurological symptoms later
• Requires lifelong steroid replacement
• Regular neurological monitoring needed

Diagnosis and Clinical Management

Diagnostic Approach

Diagnosis involves multiple modalities:

Biochemical Testing:

• Plasma VLCFA profile: Elevated C26:0, C26:1, and C26:1/C22:0 ratio
• Plasma pipecolic acid: Elevated in peroxisomal disorders
• Very long-chain ceruloplasmin: Abnormal pattern

• ABCD1 sequencing: Identifies pathogenic variants
• Deletion/duplication analysis: Detects large rearrangements
• Family testing: Carrier identification

• Brain MRI: Characteristic parieto-occipital white matter lesions
• Spinal MRI: Cord atrophy in AMN
• Adrenal imaging: May show atrophy

Clinical Management Guidelines

Standard of Care:

Treatment Response Monitoring:

• VLCFA levels: Response to therapy
• MRI: Disease progression or treatment effect
• Clinical exams: Functional assessment
• NfL levels: Emerging biomarker for treatment response

Quality of Life Considerations

Patients and families face significant challenges:

• Cognitive and behavioral impacts
• Physical disability progression
• Educational and vocational limitations
• Psychological burden
• Financial costs of care

Research landscape and Future Directions

Current Clinical Trials

Active trials are investigating:

• Gene therapy optimization: Improved vectors and delivery
• Small molecule therapies: VLCFA reduction and neuroprotection
• Cell therapy: Enhanced hematopoietic cell approaches
• Biomarker development: Better outcome measures

Emerging Understanding

Recent research has revealed:

• ABCD1 deficiency affects multiple cellular pathways beyond VLCFA metabolism
• Neuroinflammation is a major driver of disease progression
• The blood-brain barrier is compromised in X-ALD
• Mitochondrial dysfunction contributes to oligodendrocyte death
• The role of peroxisome-oxidation coupling in neuronal health

Prevention Strategies

Prevention approaches include:

• Prenatal diagnosis: For at-risk pregnancies
• Preimplantation genetic testing: For families with known mutations
• Newborn screening: Early detection and intervention
• Carrier testing: For at-risk family members

Animal Models

Multiple models contribute to understanding:

Mouse Models:

• Abcd1 knockout: VLCFA elevation, mild phenotype
• Abcd1/Abcd2 double knockout: More severe phenotype
• Humanized models: Express human ABCD1

• Morpholino knockdown models
• Transgenic lines expressing mutant ABCD1
• Drug screening platforms

• Patient-derived fibroblasts
• iPSC-derived neurons and oligodendrocytes
• Organoid systems

Global Perspective

X-ALD incidence varies by population:

• Higher in certain populations (e.g., French Canadians)
• Founder mutations in specific regions
• Newborn screening implementation varies globally
• Access to treatment differs significantly

• Patient registries
• Shared data repositories
• Clinical trial networks
• Advocacy organizations

Economic Considerations

The cost of X-ALD care is substantial:

• Diagnostic testing
• Ongoing monitoring
• Treatment costs (gene therapy >$3 million)
• Supportive care
• Lost productivity

Summary of Key Points

ABCD1 is essential for peroxisomal VLCFA import and metabolism. Mutations cause X-ALD, a progressive neurodegenerative disorder affecting cerebral white matter and the adrenal gland. Key aspects include:

Pathway Diagram

The following diagram shows the key molecular relationships involving ABCD1 — ATP Binding Cassette Subfamily D Member 1 discovered through SciDEX knowledge graph analysis: